Fertility News and Research

RSS

U-M research results show potential for discovering new avenues for anti-aging drugs

A team of University of Michigan scientists has found that suppressing a newly discovered gene lengthens the lifespan of roundworms. Scientists who study aging have long known that significantly restricting food intake makes animals live longer. But the goal is to find less drastic ways to achieve the same effect in humans someday. The U-M results offer promising early evidence that scientists may succeed at finding targets for drugs that someday could allow people to live longer, healthier lives.

19 Aug 2010

Cougar myth busted

A new study shows that the phenomenon of the “cougar” where an older woman seeks a younger partner is a myth, confined to the world of celebrities. The study looked into online dating and was conducted by the University of Wales Institute, Cardiff (UWIC). The study found the conventional – men looking for younger and attractive women and women looking for older and wealthier men.

18 Aug 2010

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

18 Aug 2010

Majority of women support single woman using IVF treatment to conceive, survey finds

A recent survey of American women aged 25-45 that gauged attitudes toward In Vitro Fertilization found that 83% of these women support a single woman using IVF to conceive if she is emotionally and financially able to care for the child.

16 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

Fertility preservation may be unsafe for leukemia patients: Study

Although the use of ovarian tissue cryopreservation and transplantation has lead to 13 live births in women with lymphoma or solid tumors, this method of fertility preservation may be unsafe for patients with leukemia, according to a recent study published online in Blood, the journal of the American Society of Hematology.

16 Aug 2010

FDA approves ellaOne for emergency contraception

HRA Pharma announced today that the US Food and Drug Administration (FDA) granted approval for ella(R) (ulipristal acetate) as a prescription-only emergency contraceptive indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.

16 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Healthy eggs require tremendous amount of zinc to reach maturity for fertilization: Research

Scientists as well as fertility doctors have long tried to figure out what makes a good egg that will produce a healthy embryo. It's a particularly critical question for fertility doctors deciding which eggs isolated from a woman will produce the best embryos and, ultimately, babies.New research reveals healthy eggs need a tremendous amount of zinc to reach maturity and be ready for fertilization,a finding that may ultimately help physicians assess the best eggs for fertility treatment, according to a study from Northwestern University.

10 Aug 2010

Repros Therapeutics receives positive feedback from FDA for Androxal

Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

9 Aug 2010

Ovulating women unconsciously dress in sexier fashion products to outdo attractive rival women

Ovulating women unconsciously buy sexier clothes, says new research from the University of Minnesota's Carlson School of Management. The study finds that ovulating women unconsciously dress to impress - doing so not to impress men, but to outdo rival women during the handful of days each month when they are ovulating.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Bisphenol A may decrease sperm quality, concentration: Research

In one of the first human studies of its kind, researchers have found that urinary concentrations of the controversial chemical Bisphenol A, or BPA, may be related to decreased sperm quality and sperm concentration.However, the researchers are quick to point out that these results are preliminary and more study is needed. Several studies have documented adverse effects of BPA on semen in rodents, but none are known to have reported similar relationships in humans.

4 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

World Congress on Fertility and Sterility to take place 12-16 September in Munich, Germany

The World Congress on Fertility and Sterility takes place every 3 years. It is the most important international congress in this fast moving field. The 20th congress will take place in Munich, Germany, from 12-16 September, 2010, just a few days before the start of the famous Oktoberfest.

30 Jul 2010

VitaPath Genetics launches VitaTrack Folate Tracker

VitaPath Genetics, the Spina Bifida Association and the National Council on Folic Acid today announced the launch of the free iPhone application—the VitaTrack Folate Tracker— which allows women to track their daily intake of folate and folic acid. Maintaining an adequate level of folic acid prior to and during pregnancy can reduce the risk of serious birth defects like Spina Bifida by up to 70%. Studies show that folic acid may also help prevent congenital heart disease, pre-term labor, and cleft lip and palate.

30 Jul 2010

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it has entered into a contract with Mokshagundam Biotechnologies, a private research organization established to develop alternative meat sources, to develop cell culture medium for use in exploration of alternative food sources derived from stem cells.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Fertility News and Research

U-M research results show potential for discovering new avenues for anti-aging drugs

Cougar myth busted

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Majority of women support single woman using IVF treatment to conceive, survey finds

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Fertility preservation may be unsafe for leukemia patients: Study

FDA approves ellaOne for emergency contraception

Repros receives US patent for Androxal

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Healthy eggs require tremendous amount of zinc to reach maturity for fertilization: Research

Repros Therapeutics receives positive feedback from FDA for Androxal

Ovulating women unconsciously dress in sexier fashion products to outdo attractive rival women

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Bisphenol A may decrease sperm quality, concentration: Research

Merck reports strong bottom-line performance in second quarter

World Congress on Fertility and Sterility to take place 12-16 September in Munich, Germany

VitaPath Genetics launches VitaTrack Folate Tracker

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News